Investor

Merlin Biosciences

Last cheque observed Nov 2006. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietGrowth equity

Series CSeries BSeries D

Cheques on record
0%of best year0cheques in 12 months, 10 on record
Since the last cheque7284days00hrs00min00sec
Median round$18MRounds led0 of 10Exits1 from the portfolioMostly inUnited Kingdom, 67%
Pitch Merlin Biosciences

Merlin Biosciences highlights

  1. 01

    10 rounds on record

  2. 02

    Mostly Series C and Series B: 50% of its rounds

  3. 03

    1 exits from the portfolio

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first10 appearances

  1. 2006

    3 rounds

  2. Nov
    NeurotechSeries B · US · neurotechusa.com$35MWith 11 others
  3. Jul
    Takeda CambridgeSeries D · GB$13MWith 2 others
  4. May
    OnyvaxSeries C · GB · onyvax.com$15MWith 4 others
  5. 2005

    2 rounds

  6. Aug
    Intercytex GroupVenture · GB · fiercebiotech.com$21MWith 4 others
  7. Jan
    Takeda CambridgeVenture · GB$9.4MWith 2 others
  8. 2004

    1 round

  9. Jan
    Cyclacel PharmaceuticalsSeries D · US · evaluategroup.com$39MWith 15 others
  10. 2003

    2 rounds

  11. Jul
    Ardana BioscienceSeries B$32MWith 4 others
  12. Jul
    PiramedSeries A · GB$13MWith 1 other
  13. 2002

    1 round

  14. Feb
    MicroscienceSeries C · GB$36MWith 3 others
  15. 2001

    1 round

  16. Jan
    EpiCept CorporationSeries C · US$13MWith 5 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

PiramedBought by Roche$160MApr 2008

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Merlin Biosciences. A count of rooms they were both in, not a relationship either has claimed.

Avlar BioVenturesInvestment firm3rounds together3i GroupPrivate equity2rounds togetherApax PartnersPrivate equity2rounds togetherBio*One CapitalCorporate VC2rounds togetherJP MorganInvestment bank2rounds togetherNIF VenturesGrowth equity2rounds togetherScottish Equity PartnersPrivate equity2rounds together

Quick answers about Merlin Biosciences

What does Merlin Biosciences invest in?

Merlin Biosciences invests most often at Series C and Series B (50% of the rounds on record).

How active is Merlin Biosciences?

10 investments on record, 0 of them in the last 12 months. The most recent was in Nov 2006.

How big are Merlin Biosciences's cheques?

The median round it joins is $18M.

Does Merlin Biosciences lead rounds?

Rarely, if at all: none of its 10 investments on record names it as the lead.

Where does Merlin Biosciences invest?

Most of the companies it backs are in the United Kingdom (67%) and the United States (33%).

Is Merlin Biosciences investing now?

No investments in the last 12 months; the latest was in Nov 2006.

Who does Merlin Biosciences invest alongside?

Most often Avlar BioVentures (3 rounds together), 3i Group (2 rounds together) and Apax Partners (2 rounds together).

What kind of investor is Merlin Biosciences?

Merlin Biosciences is a growth equity firm.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it